Background: Anticancer drugs are characterized by a narrow therapeutic window and
significant inter-patient variability in therapeutic and toxic effects. Current body surface area …

Drugs are to the medical oncologist what the scalpel is to the surgical oncologist. These are
our basic tools, and using them correctly and deftly should be the most fundamental action in …

Targeted therapies are now considered an integral component in the treatment
armamentarium for many malignancies, and the approach to developing these drugs needs …

TO THE EDITOR: The article by Griggs et al1 gave guidelines for appropriate dosing for
obese adult patients that use body-surface area (BSA) to determine dose. The oncology …

Dosages of anticancer drugs are usually calculated on the basis of a uniform standard, the
body surface area (BSA). Although many physiological functions are proportionate to BSA …

Cytotoxic chemotherapy is characterised by a low therapeutic index and significant
variability in therapeutic and toxic effects. In an attempt to reduce this variability, most …

Anticancer agents often have a narrow therapeutic index (TI), requiring precise dosing to
ensure sufficient exposure for clinical activity while minimizing toxicity. These agents …

Selection of the maximum tolerated dose (MTD) as the recommended dose for registration
trials based on a dose-escalation trial using variations of an MTD/3+ 3 design often occurs in …

Project Optimus is a US Food and Drug Administration Oncology Center of Excellence
initiative aimed at reforming the dose selection and optimization paradigm in oncology drug …

Variation between individuals in response to chemotherapy is of great clinical significance,
and variation in drug exposure is a major contributor to it. Reducing this variability in drug …